RxDoctor Payments Data

Richard Moseley

Gastroenterology · Boulder, CONPI 1447343843

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (44.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Gilead accounts for 65.0% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2019 at $4,889 and has fallen 98.6% since, to $70 in 2021.

$5,803in general payments, 2019–2025

Across 171 payments — averaging $33.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$4K
  • AbbVie$898
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$448
  • Takeda Pharmaceuticals U.S.A., Inc.$136
  • UCB, Inc.$112
  • Shionogi Inc$109
  • plus $330 from 7 others

What the payments were for

  • Consulting fees$2,60045%
  • Travel & lodging$60110%
  • Food & beverage$2,60245%

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,803 in reported general payments places this provider in the 70th percentile of 304 gastroenterology providers in Colorado.

See all gastroenterology providers in Colorado →

Other gastroenterology in Boulder

See the full list for Colorado →

Where these figures come from

Is this you, or does something look wrong? →